Marshall Wace’s TScan Therapeutics TCRX Stock Holding History

Marshall Wace’s Portfolio TCRX Stock Details TCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$674K	Buy	687,364 +450,018	+190%	+$480K	﹤0.01%	2389
2026 Q1	$240K	Sell	237,346 -101,894	-30%	-$109K	﹤0.01%	2715
2025 Q4	$339K	Buy	339,240 +292,610	+628%	+$424K	﹤0.01%	2403
2025 Q3	$84.9K	Sell	46,630 -7,048	-13%	-$12.5K	﹤0.01%	2675
2025 Q2	$77.8K	Buy	+53,678	New	+$77.5K	﹤0.01%	2567
2025 Q1	–	Sell	-43,969	Closed	-$134K	–	3083
2024 Q4	$134K	Sell	43,969 -121,191	-73%	-$549K	﹤0.01%	2413
2024 Q3	$822K	Sell	165,160 -142,327	-46%	-$859K	﹤0.01%	1728
2024 Q2	$1.8M	Buy	307,487 +116,316	+61%	+$916K	﹤0.01%	1428
2024 Q1	$1.52M	Buy	191,171 +80,620	+73%	+$507K	﹤0.01%	1486
2023 Q4	$645K	Buy	+110,551	New	+$506K	﹤0.01%	1623

Other funds holding TCRX

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

DMC

Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Marshall Wace's TCRX Position: Q2 2026 in Review

Marshall Wace increased its TScan Therapeutics (TCRX) stake by 190% in Q2 2026, buying an estimated $480K and bringing the position to 687,364 shares worth $674K. The position accounts for ﹤0.01% of the portfolio, ranked #2389.

Marshall Wace first reported a position in TCRX in Q4 2023 and has held it in 10 quarters since. The position peaked at $1.8M in Q2 2024. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

Marshall Wace held 687,364 shares of TScan Therapeutics worth $674K as of Q2 2026.
Marshall Wace bought 450,018 TScan Therapeutics shares in Q2 2026, an estimated $480K.
TScan Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2389 holding.
Marshall Wace first reported a position in TScan Therapeutics in Q4 2023 and has held it in 10 quarters since.
Marshall Wace's TScan Therapeutics position peaked at $1.8M in Q2 2024.
60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.